Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.


Serval ID
Article: article from journal or magazin.
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Clinical therapeutics
Cardoso E., Guidi M., Khoudour N., Boudou-Rouquette P., Fabre E., Tlemsani C., Arrondeau J., Goldwasser F., Vidal M., Schneider M.P., Wagner A.D., Widmer N., Blanchet B., Csajka C.
1879-114X (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Erlotinib is an oral first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for non-small cell lung cancers (NSCLC) with EGFR-activating mutations. Older patients experience more toxicities compared with younger patients at the standard recommended dose of 150 mg once daily. The aims of this study were to describe the pharmacokinetic profile of erlotinib in unselected patients with NSCLC, to quantify and explain its variability, to challenge the standard recommended dose in older patients, and to propose clinical recommendations for the therapeutic management of patients taking erlotinib.
A population pharmacokinetic model was developed using erlotinib plasma concentrations collected from patients with NSCLC participating in a routine therapeutic drug monitoring program (with the nonlinear mixed effect modeling program NONMEM). Relevant demographic characteristics, clinical factors, and co-medications were tested as potential covariates. An independent dataset was used for model validation. Simulations based on the final model allowed comparison of expected erlotinib concentrations under standard and alternative dosing regimens for smokers and for several age groups.
A total of 481 erlotinib plasma concentrations from 91 patients with NSCLC were used for model building and 239 plasma drug concentrations from 107 patients for model validation. A one-compartment model with first-order absorption and elimination provided the best fit. Average erlotinib CL/F with interindividual variability (%CV) was 3.8 L/h (41.5%), and V/F was 166 L (53.8%). The absorption rate constant was 1.48 h <sup>-1</sup> . The external validation showed a negligible bias of -4% (95% CI, -7 to -1) in the individual predictions, with a precision of 23%. Current smoking and use of proton pump inhibitors were associated with higher CL/F, whereas age was associated with lower CL/F. Simulations suggest that a lower dose in older patients would decrease the risk of overexposure.
This large cohort study confirms the substantial interindividual variability in erlotinib plasma exposure and the impact of smoking and proton pump inhibitor intake. This large variability in erlotinib pharmacokinetics indicates that the standard recommended dose of 150 mg once daily is likely not appropriate to reach the expected concentrations in each patient. Concentration monitoring should be performed to individually adjust the erlotinib dosing regimen. The observed decrease in erlotinib CL/F with age suggests that a lower starting daily dose of 100 mg with concentration-guided dose adjustment would prevent overexposure and potential toxicity in older frail patients with co-morbidities.
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/blood, Antineoplastic Agents/pharmacokinetics, Carcinoma, Non-Small-Cell Lung/blood, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/metabolism, Drug Monitoring, Erlotinib Hydrochloride/administration & dosage, Erlotinib Hydrochloride/blood, Erlotinib Hydrochloride/pharmacokinetics, Female, Humans, Lung Neoplasms/blood, Lung Neoplasms/drug therapy, Lung Neoplasms/metabolism, Male, Middle Aged, Models, Biological, Protein Kinase Inhibitors/administration & dosage, Protein Kinase Inhibitors/blood, Protein Kinase Inhibitors/pharmacokinetics, Proton Pump Inhibitors/therapeutic use, Smoking/metabolism, erlotinib, older patients, population pharmacokinetics, therapeutic drug monitoring
Web of science
Create date
13/07/2020 9:18
Last modification date
14/03/2023 6:49
Usage data